Table 1.
Patient and baseline characteristics.
| Characteristic | Durvalumab (n = 38) |
Durvalumab + Tremelimumab (n = 39) |
|---|---|---|
| Median Age, years (range) | 64 (45-78) | 67 (52-84) |
| ECOG Status | ||
| 0 | 26 (68.4%) | 24 (61.5%) |
| 1 | 12 (31.6%) | 15 (38.5%) |
| Race, n (%) | ||
| White | 27 (71.1%) | 27 (69.2%) |
| African-American | 4 (10.5%) | 5 (12.8%) |
| Asian | 4 (10.5%) | 2 (5.1%) |
| Unknown/Other | 3 (7.9%) | 5 (12.8%) |
| Stage at Diagnosis, n (%) | ||
| Stage I | 9 (23.7%) | 10 (25.6%) |
| Stage II | 4 (10.5%) | 1 (2.6%) |
| Stage III | 11 (28.9%) | 16 (41.0%) |
| Stage IV | 14 (36.8%) | 12 (30.8%) |
| Histology, n (%) | ||
| Endometrioid, Grade 1/2 | 7 (18.4%) | 8 (20.5%) |
| dMMR | 3 (7.9%) | 2 (5.1%) |
| pMMR | 4 (10.5%) | 6 (15.4%) |
| Endometrioid, Grade 3 | 0 | 8 (20.5%) |
| dMMR | 0 | 0 |
| pMMR | 0 | 7 (17.9%) |
| unknown | 0 | 1 (2.6%) |
| Serous | 11 (28.9%) | 6 (15.4%) |
| dMMR | 0 | 1 (2.6%) |
| pMMR | 10 (26.3%) | 5 (12.8%) |
| unknown | 1 (2.6%) * | 0 |
| Clear Cell | 5 (13.2%) | 1 (2.6%) |
| dMMR | 0 | 0 |
| pMMR | 5 (13.2%) | 1 (2.6%) |
| Carcinosarcoma | 6 (15.8%) | 10 (25.6%) |
| dMMR | 0 | 0 |
| pMMR | 5 (13.2%) | 9 (23.0%) |
| unknown | 1 (2.6%) * | 1 (2.6%) |
| Mixed/Dedifferentiated Histology | 9 (23.7%) | 6 (15.4%) |
| dMMR | 2 (5.3%) | 4 (10.3%) |
| pMMR | 7 (18.4) | 1 (2.6%) |
| unknown | 0 | 1 (2.6%) * |
| All Histology Total | ||
| dMMR | 5 (13.2%) | 4 (10.3%) |
| pMMR | 31 (81.6%) | 32 (82.0%) |
| unknown | 2 (5.3%) * | 3 (7.7%) * |
| Prior Cytotoxic Therapy, n (%) | ||
| 1 Line | 13 (34.2%) | 9 (23.1%) |
| 2 Lines | 16 (42.1%) | 16 (41.0%) |
| 3 Lines | 9 (23.7%) | 14 (35.9%) |
| Prior Radiation, n (%) | ||
| Yes | 20 (52.6%) | 26 (66.7%) |
| No | 18 (47.4%) | 13 (33.3%) |
ECOG, Eastern Cooperative Oncology Group; dMMR, mismatch repair deficient; pMMR, mismatch repair proficient.
*
Microsatellite Stable confirmed with unknown MMR status.